Share on StockTwits

Equities research analysts at Leerink Swann dropped their target price on shares of Dyax Corp. (NASDAQ:DYAX) from $12.00 to $7.00 in a research note issued to investors on Thursday, Analyst RN reports. The firm currently has a “market perform” rating on the stock. Leerink Swann’s price objective would indicate a potential upside of 6.06% from the company’s current price.

DYAX has been the subject of a number of other recent research reports. Analysts at BofA Merrill Lynch reiterated a “buy” rating on shares of Dyax Corp. in a research note on Thursday. They now have a $9.00 price target on the stock. Finally, analysts at Bank of America initiated coverage on shares of Dyax Corp. in a research note on Tuesday, April 22nd. They set a “buy” rating and a $9.00 price target on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $11.33.

Shares of Dyax Corp. (NASDAQ:DYAX) traded up 0.15% on Thursday, hitting $6.60. The stock had a trading volume of 1,444,358 shares. Dyax Corp. has a 52 week low of $2.26 and a 52 week high of $10.99. The stock’s 50-day moving average is $7. and its 200-day moving average is $8.2. The company’s market cap is $832.0 million.

Dyax Corp. (NASDAQ:DYAX) last released its earnings data on Wednesday, April 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). Analysts expect that Dyax Corp. will post $-0.21 EPS for the current fiscal year.

Dyax Corp. (NASDAQ:DYAX), is a biopharmaceutical company with two business elements: Angioedema Franchise and Phage Display Licensing and Funded Research Program.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.